Transition Bio
Transition Bio is a biotechnology company pioneering drug discovery through a unique condensate drug discovery platform that integrates droplet microfluidics, advanced cellular imaging, and machine learning. The company leverages molecular insights from collaborations with Harvard's Weitz Lab and the University of Cambridge's Knowles Lab to optimize chemical matter impacting biomolecular condensates, enabling novel therapeutic development. Transition Bio's platform is differentiated by its end-to-end approach combining biophysical data and AI to accelerate discovery in oncology and other disease areas. The company has secured significant Series A funding and assembled a leadership team with deep expertise in biophysics, drug discovery, and life sciences, positioning it as a leader in condensate-based drug development with global operations in the US and UK.
Transition Bio
Transition Bio is a biotechnology company pioneering drug discovery through a unique condensate drug discovery platform that integrates droplet microfluidics, advanced cellular imaging, and machine learning. The company leverages molecular insights from collaborations with Harvard's Weitz Lab and the University of Cambridge's Knowles Lab to optimize chemical matter impacting biomolecular condensates, enabling novel therapeutic development. Transition Bio's platform is differentiated by its end-to-end approach combining biophysical data and AI to accelerate discovery in oncology and other disease areas. The company has secured significant Series A funding and assembled a leadership team with deep expertise in biophysics, drug discovery, and life sciences, positioning it as a leader in condensate-based drug development with global operations in the US and UK.